Stress echocardiography for left ventricular diastolic dysfunction detection in patients with non-severe chronic obstructive pulmonary disease: a cross-sectional study

Aim To assess whether the simultaneous performance of exercise stress echocardiography and cardio-pulmonary testing (ESE-CPET) may facilitate the timely diagnosis of subclinical left ventricular diastolic dysfunction (LVDD) in patients with non-severe chronic obstructive pulmonary disease (COPD), preserved left ventricular systolic function, and exertional dyspnea or exercise intolerance.

Methods This cross-sectional study, conducted between May 2017 and April 2018, involved 104 non-severe COPD patients with exertional dyspnea and preserved ejection fraction who underwent echocardiography before CPET and 1-2 minutes after peak exercise. Based on the peak E/e' ratio, patients were divided into the group with stress-induced LVDD – E/e'>15 and the group without stress-induced LVDD. We assessed the association between LVDD and the following CPET variables: minute ventilation, peak oxygen uptake (VO2), ventilatory efficiency, heart rate reserve, and blood pressure.

Results During ESE-CPET, stress-induced LVDD occurred in 67/104 patients (64%). These patients had lower work load, peak VO2, O2 pulse, and minute ventilation (VE), and higher VE/VCO2 slope than patients without stress-induced LVDD (35.18 ± 10.4 vs 37.01 ± 11.1, P<0.05). None of the CPET variables correlated with E/e'.

Conclusion Combined ESE-CPET may distinguish masked LVDD in patients with non-severe COPD with exertional dyspnea and preserved left ventricular systolic function. None of the CPET variables was a predictor for subclinical LVDD.
During the last decade, chronic obstructive pulmonary disease (COPD) has caused significant morbidity and mortality (1). COPD patients have greater than 2-fold excess risk of cardiovascular events and greater than 4-fold risk of developing chronic heart failure or coronary artery disease (2,3). Even patients with mild COPD have sub-clinical functional and structural changes, which, as airway obstruction gradually progresses, evolve to an overt disease (4). Therefore, an early detection and proper risk assessment are important for the control and prevention of cardiovascular comorbidities in COPD.

Studies using magnetic resonance imaging established that patients with mild COPD without diseases, hypertension, or diabetes have arterial stiffness and myocardial fibrosis (5-8). Both pathologies are manifestations of the systemic effects of COPD and are a precondition for left ventricular diastolic dysfunction (LVDD) (9,10). In addition, chest wall hyperinflation and intra-thoracic pressure gradients may influence left ventricular (LV) pre-load and/or afterload (11). Thus, systemic and hemodynamic effects associated with the pathophysiological abnormalities of COPD are preconditions for LVDD.

Dyspnea and exercise intolerance are common symptoms of both COPD and heart failure with preserved ejection fraction (12,13). This is why there is need for cardio-respiratory parameters that discriminate between cardiac and respiratory nature of dyspnea or diminished physical activity (14,15).

There are no studies dealing with the problem of masked heart failure in COPD population. We hypothesized that the simultaneous performance of exercise stress echocardiography and cardio-pulmonary testing (ESE-CPX) may facilitate the timely diagnosis of subclinical LVDD in patients with non-severe COPD, preserved left ventricular systolic function (LVSF), and exertional dyspnea or exercise intolerance. The aims of the current study are to detect the frequency of exercise-induced LVDD in non-severe, non-symptomatic at rest COPD patients and to establish CPET parameters that can be applied as surrogate markers for masked LVDD.

MATERIALS AND METHODS

Patients and study protocol

This cross-sectional study involved 224 clinically stable outpatients diagnosed with COPD at the University Hospital for Respiratory Diseases “St. Sophia” in Sofia, Bulgaria. Only 163 of them met the inclusion criteria – FEV1 > 50% and lack of overt cardiovascular diseases. All patients had exertional dyspnea and preserved left ventricular systolic function. The following exclusion criteria were used: 1) LVEF<50%; 2) LVDD at rest more than first grade; 3) echocardiographic signs of systolic pulmonary arterial hypertension; 4) valvular heart disease; 5) documented cardiomyopathy; 6) severe uncontrolled hypertension (systolic blood pressure >180 mm Hg and diastolic blood pressure >90 mm Hg); 7) atrial fibrillation or malignant ventricular arrhythmia; 8) anemia; 9) cancer; 10) chronic kidney disease; 11) recent chest or abdominal surgery; 12) recent exacerbation (during the last three months); 13) recent change (during the last three months) in medical therapy. Based on these criteria, 59 patients were excluded, and 104 patients (64 men; mean age of 62.9 ± 7.5 years) were considered eligible (Figure 1). The recruitment period lasted between May 2017 and April 2018. The study was approved by the Committee of Ethics of Science Research, Medical University Sofia (protocol 5/12.03.2018). All the patients signed informed consent before entering the study.

Patients’ data included general demographic information, self-reported medical history, and concomitant medication. Demographic and clinical data are presented in Table 1.

Pulmonary function testing

All participants underwent preliminary clinical examination that included chest x-ray, spirometry, electrocardiogram, and echocardiography. The patients eligible for the study performed spirometry and exercise stress test. Both tests were performed on Vyntus (Carefusion, Baesweiler, Germany) following the manufacturer’s instructions. Spirometry was performed after bronchodilation test with the application of 400 mg salbutamol. Following the ERS guidelines, a post-bronchodilation ratio of FEV1/FVC<70% was used as a diagnostic criterion of COPD (16). Only patients with mild/moderate airway obstruction (FEV1 > 50%) were selected.

Six-minute walk test

Six-minute walk test was performed in accordance with the ATS guidelines (17). It was done on a separate day after the initial visit and after the exercise stress test and stress echocardiography. Participants were instructed to walk the previously measured 30-m distance in a hospital corridor. SpO2, heart rate, and arterial blood pressure were obtained before and during the recovery period, 1 minute after the end of the test.
Stress test protocol – cardio-pulmonary exercise testing (CPET)

After the clinical examination and spirometry, all the patients underwent symptom-limited incremental exercise stress test on a supine bicycle in accordance with the guidelines (18). Gas and flow sensors were calibrated before each test. Patients underwent standard electrocardiography through the whole exercise test and manual blood pressure measurements and heart rate recordings at the end of every stage.

A continuous RAMP protocol was applied – two minutes of unloaded pedaling (rest phase – 0W), a three-minute warm-up phase (20W), and the test phase including 20 W/2-min load increments. Patients were instructed to pedal with 60 rotations per minute.

Expiratory gases were analyzed by breath-by-breath analysis. Peak values of oxygen consumption, carbon dioxide production, and ventilatory efficiency (VE/VCO₂) are presented as the highest 30-second average value obtained during the last stage of the exercise test. These values were used to estimate peak respiratory exchange ratio (RER). RER>1.00 was considered as a maximum effort. The modified Borg scale was applied for peak dyspnea evaluation. Heart rate recovery was defined as the difference between peak heart rate and heart rate during the first minute of recovery.

Electrocardiography

Twelve-lead electrocardiography was performed during the four phases of the cardio-pulmonary test. The test was terminated because of exertion – exercise-limiting dyspnea, fatigue, claudication, or severe chest pain at patient’s request or because of clinical indications – emergence of repolarization ST-T changes, decrease in systolic blood pressure of more than 20 mm Hg, increase in systolic blood pressure of more than 220 mm Hg, or malignant arrhythmias.

Echocardiography methods

Echocardiography included the generally applied approaches of M-mode and two-dimensional and
Doppler echocardiography. Routine structural and hemodynamic indices of both chambers were measured following the guidelines (19). The systolic function of the left ventricle was defined by Simpson’s modified rule. The diastolic function of both ventricles was evaluated by the E/A ratio at rest (20) and tissue Doppler analysis as a more precise approach. The e’ value was defined as the average of the medial and lateral measurements of the mitral annulus. The peak of the average E/e’ ratio greater than 15 was considered as a marker for stress induced LVDD.

The dimensions of the right ventricle were assessed from the long-axis parasternal and apical four chamber view (21). TAPSE and S peak velocity were analyzed for RV systolic function evaluation. RVWT was measured in end-diastole. Systolic pulmonary arterial pressure was calculated by Bernoulli equation and by the acceleration time (AT) (22,23). Right atrium volume index (RAVI) was measured at end-systole by Simpson’s modified rule. Reference range for RAVI averages 25 ± 7 mL/m² in men and 21 ± 6 mL/m² in women. Stress induced RV diastolic dysfunction was considered if stress induced E/e’ ratio was higher than 6. All parameters were measured at end-expiration and in triplicate during different heart cycles.

**Statistical analysis**

Descriptive statistics was used to summarize demographic and clinical data. Normality of distribution was tested with the Kolmogorov-Smirnov test. Continuous variables are expressed as mean values ± standard deviation, while categorical variables are expressed as proportions. Normally distributed variables were compared between the patients with and without LVDD with the t test, whereas non-normally variables were compared with the Mann-Whitney-U test. Categorical variables were compared with the χ² test or Fisher exact test. The correlation between CPET parameters and the presence of LVDD was assessed by the Spearman’s rank correlation test. The level of significance was set at P < 0.05. The analyses were conducted in SPSS, v. 13.0 (SPSS Inc. Chicago, IL, USA).

**TABLE 1. Clinical and demographic characteristics of patients with and without left ventricular diastolic dysfunction (LVDD)**

| Demographic data | without stress-induced LVDD (N = 37) | with stress-induced LVDD (N = 67) | P  |
|------------------|------------------------------------|----------------------------------|----|
| Age (years), mean ± standard deviation | 60.44 ± 7.72 | 64.16 ± 6.97 | 0.143* |
| Male, n | 21 | 16 | 0.298‡ |
| Current smokers | 23 (62) | 39 (58) | 0.176‡ |
| Former smokers | 4 (11) | 17 (25) | 0.981‡ |
| Non-smokers | 10 (27) | 11 (17) | 0.375‡ |
| Pack years, mean ± standard deviation | 27.21 ± 6.33 | 33.79 ± 3.04 | 0.491‡ |
| Body mass index (kg/m²), mean ± standard deviation | 27.38 ± 4.58 | 26.65 ± 6.7 | 0.207‡ |
| Clinical data | | | |
| systolic blood pressure (mmHg), mean ± standard deviation | 128.16 ± 9.68 | 128.17 ± 11.39 | 0.217‡ |
| diastolic blood pressure (mmHg), mean ± standard deviation | 81.11 ± 5.54 | 82.31 ± 6.53 | 0.206‡ |
| Discharge medication | | | |
| inhaled β2 agonists | 26 (70) | 67 (100) | 0.721‡ |
| inhaled anticholinergic medications | 17 (46) | 38 (57) | 0.409‡ |
| inhaled corticosteroids | 18 (48) | 50 (75) | 0.031‡ |
| angiotensin converting enzyme Inhibitors | 22 (59) | 54 (81) | 0.026‡ |
| β blockers | 7 (19) | 22 (33) | 0.027‡ |
| diuretics | 25 (67) | 52 (78) | 0.043‡ |
| Medical history | | | |
| diabetes | 6 (16) | 13 (19) | 0.721‡ |
| systemic hypertension | 23 (62) | 54 (81) | 0.483‡ |
| coronary artery disease | 1 (2) | 12 (18) | 0.492‡ |

*Unpaired t test. †Mann-Whitney U test. ‡Chi square test.
RESULTS

Participants had a mean age of 62.9 ± 7.5 years and body mass index of 27.02 ± 6.3 kg/m². According to the stress echocardiography results, they were divided into the group with stress-induced LVDD and the group without stress-induced LVDD. The groups did not differ in anthropometric, respiratory (Table 2), or other clinical characteristics. After ESE-CPX, 64% (67/104) of patients showed stress-induced LVDD (E/e’ > 15). Other LV and RV structural and functional parameters are shown in Table 3. Patients with stress-induced LVDD had a significant increase in systolic pulmonary arterial pressure (baseline 27.92 ± 2.97 mmHg vs stress induced 38.80 ± 3.83 mmHg, P < 0.0001) (Table 3). Non-severe COPD patients with stress-induced LVDD compared with non-severe COPD patients without stress-induced LVDD showed limited exercise capacity (Table 4), achieving lower load, VO₂, and O₂-pulse. They performed with significantly higher VE/VCO₂ slope (35.18 ± 10.4 vs 37.01 ± 11.11, P = 0.032; Table 4). None of the CPET parameters correlated with stress induced LVDD.

DISCUSSION

This study found 1) a high frequency (64%) of stress-induced LVDD in non-severe COPD patients with exertional dyspnea and preserved LV ejection fraction; 2) stress-induced elevation of systolic pulmonary arterial pressure (>35 mm Hg) and a reduced functional capacity, as measured by both CPET and 6-min walk, in participants with stress-induced LVDD; 3) difference in CPET variables between patients with and without stress-induced LVDD, but no correlation of these variable to stress E/e’. These results only partially confirm our hypothesis, as we expected that in addition to the high prevalence of stress-induced LVDD, some CPET parameters would predict LVDD. The reasons for the discrepancy may be the complex lung-heart interaction during exercise and multifactorial nature of LVDD.

COPD is a multi-systemic disease that remains a worldwide leading cause of disability (24,25). Compared with the general population, COPD patients bear a two to 5-fold increased risk of cardiovascular complications, with cardiovascular morbidity as the cause of death in a third of these patients (26). COPD is an independent predictor for vascular damage (27,28) and is associated with increased arterial stiffness and myocardial fibrosis, which may be present in COPD patients free of manifest cardiovascular diseases (11,28-32). Both pathological abnormalities are a precondition for a higher prevalence of LVDD in COPD patients (6,13). The link between LVDD and COPD is complex and is probably a result of various mechanisms – mechanical/functional (deterioration in FEV₁, emphysema, hyperinflation) (5,11,33-35), biological (systemic inflammation, hypoxemia, endothelial dysfunction) (36-38), and neurohumoral (excess sympathetic nerve activity) (39). Each of these may be a trigger in a certain phenotype of COPD patients (40-42).

Cardio-respiratory parameters may discriminate between the cardiac and respiratory nature of dyspnea/diminished physical activity and facilitate the early diagnosis of cardiovascular pathology in COPD. Our results, however, show that none of these parameters correlated with stress induced LVDD (E/e’ > 15). These results differ from data obtained in the general population, which had a significantly

| TABLE 2. Respiratory parameters of patients with and without left ventricular diastolic dysfunction (LVDD)* |
|-----------------------------|-----------------------------------------------|-----------------------------------------------|----------------|----------|
| Parameter, mean ± standard deviation | Patients without stress-induced LVDD (N = 37) | Patients with stress-induced LVDD (N = 67) | P*         |
| Respiratory function        |                                               |                                               |             |
| FVC, l/min                  | 2.60 ± 0.93                                  | 2.38 ± 0.74                                  | 0.213       |
| FEV₁, l/min                 | 1.71 ± 0.66                                  | 1.47 ± 0.42                                  | 0.408       |
| FEV₁/FVC %                  | 62.12 ± 9.46                                 | 53.87 ± 14.39                                | 0.764       |
| mMRC                        | 1.55 ± 0.49                                  | 1.70 ± 0.79                                  | 0.891       |
| Acid-base balance           |                                               |                                               |             |
| pH                          | 7.44 ± 0.03                                  | 7.43 ± 0.03                                  | 0.329       |
| O₂, mmHg                    | 68.09 ± 10.44                                | 67.48 ± 10.19                                | 0.298       |
| CO₂, mmHg                   | 35.96 ± 9.49                                 | 37.14 ± 8.03                                 | 0.275       |
| BE, mmol/L                  | 3.80 ± 5.63                                  | 2.39 ± 1.79                                  | 0.872       |
| HCO₃⁻, mmol/L               | 21.73 ± 6.46                                 | 24.28 ± 3.48                                 | 0.328       |
| Saturation %                | 94.15 ± 2.00                                 | 94.01 ± 2.27                                 | 0.763       |

*FVC – forced vital capacity; FEV₁ – forced expiratory volume 1; mMRC – modified Medical Research Council; BE – base excess.
†Mann-Whitney U test.
lower prevalence of exercise-induced LVDD. Nedeljkovic et al (43) performed ESE in 87 patients with exertional dyspnea, hypertension, and normal left ventricular function, 9.2% of whom demonstrated E/e’>15. In the study by Talal et al (44), among 87 patients with exertional dyspnea, 9% had E/A<0.75. Guazzi et al (45) reported an association between diastolic dysfunction (E/e’ ratio) and peak oxygen consumption, ventilatory efficiency, and heart rate recovery. In patients with normal echocardiography at rest, peak E/e’ ratio >15 correlated best to ventilatory efficiency (43). VE/VO2 ratio as the best predictor of stress E/e’ was also confirmed in a diastolic heart failure group (45).

Since LVDD is associated with an increased risk of exacerbations and mortality, its timely diagnosis in non-severe COPD is important for disease management. As none of the clinical, ventilatory, cardio-pulmonary, and echocardiographic characteristics can predict stress-induced LVDD in

| TABLE 3. Echocardiographic characteristics of patients with and without left ventricular diastolic dysfunction (LVDD)* |
|---------------- |---------------- |---------------- |---------------- |---------------- |
| Parameter, mean ± standard deviation | Patients without stress-induced LVDD | Patients with stress-induced LVDD | P† |
| LV structural parameters | | | |
| LVEF, %, Teicholz | 62.69 ± 4.02 | 62.09 ± 6.34 | 0.653 |
| LVEF, %, Simpson | 63.05 ± 3.80 | 60.40 ± 6.44 | 0.016 |
| TDD, mm | 52.22 ± 5.16 | 50.98 ± 4.61 | 0.253 |
| TSD, mm | 33.94 ± 4.37 | 33.48 ± 4.72 | 0.275 |
| TDV, mL | 131.88 ± 30.18 | 122.44 ± 25.19 | 0.181 |
| TSV, mL | 49.63 ± 14.85 | 46.80 ± 16.32 | 0.187 |
| Septum, mm | 12.01 ± 1.01 | 12.00 ± 1.19 | 0.897 |
| PW, mm | 12.05 ± 0.94 | 12.03 ± 1.14 | 0.981 |
| LV functional parameters at rest | | | |
| E/A ratio | 0.94 ± 0.70 | 0.98 ± 0.32 | 0.420 |
| E’ average, cm/s | 8.36 ± 1.47 | 9.62 ± 1.69 | 0.003 |
| E/e’ average ratio | 7.30 ± 1.89 | 7.12 ± 2.59 | 0.736 |
| LV functional parameters after exercise stress test | | | |
| E/A ratio | 0.92 ± 0.68 | 1.79 ± 0.42 | <0.0001 |
| E’ average, cm/s | 10.55 ± 2.24 | 6.78 ± 0.90 | <0.0001 |
| E/e’ average | 9.04 ± 1.89 | 17.18 ± 3.17 | <0.0001 |
| RV structural parameters | | | |
| RAVI, mL/m2 | 18.29 ± 2.65 | 23.04 ± 2.65 | <0.0001 |
| RVWT, mm | 5.41 ± 1.08 | 6.53 ± 0.53 | <0.0001 |
| RV diameter parasternal, mm | 28.02 ± 2.83 | 28.25 ± 2.25 | 0.687 |
| RV basal, mm | 36.30 ± 2.97 | 37.12 ± 3.25 | 0.095 |
| RV med, mm | 24.01 ± 3.43 | 27.24 ± 2.06 | <0.0001 |
| RV functional parameters at rest | | | |
| E/A ratio | 0.92 ± 0.31 | 0.67 ± 0.14 | <0.0001 |
| E/e’ average | 4.72 ± 1.42 | 4.64 ± 1.01 | 0.64 |
| TAPSE, mm | 23.86 ± 2.82 | 22.39 ± 1.82 | 0.009 |
| AT, ms | 170.39 ± 12.08 | 169.59 ± 12.14 | 0.737 |
| sPAP , mmHg | 26.80 ± 2.42 | 27.92 ± 2.97 | <0.0001 |
| RV functional parameters after exercise stress test | | | |
| E/A ratio | 1.39 ± 0.27 | 1.37 ± 0.21 | 0.830 |
| E/e’ average | 4.82 ± 1.6 | 9.60 ± 2.74 | <0.0001 |
| TAPSE, mm | 21.25 ± 0.95 | 21.34 ± 1.85 | 0.324 |
| AT, ms | 163.33 ± 15.99 | 103.62 ± 16.04 | <0.0001 |
| sPAP , mmHg | 31.86 ± 2.17 | 38.80 ± 3.83 | <0.0001 |

*LVEF – left ventricular ejection fraction; TDD – telediastolic diameter; TSD – telesystolic diameter; TDV – tissue Doppler velocity; TSV – total stroke volume; PW – posterior wall thickness at end-diastole; RV – right ventricle; RAVI – right atrium volume index; RVWT – right ventricular wall thickness; TAPSE – tricuspid annular plane systolic excursion; SPAP –systolic pulmonary arterial pressure.
†Mann-Whitney U test.
non-severe COPD, the combined ESE can facilitate its early diagnosis.

Our study has the following limitations: 1) the relatively small sample size; 2) the lack of body plethysmography for the measurement of hyperinflation and the lack of diffusion capacity measurements, which are informative for the proper assessment of dyspnea; 3) measurements were performed at the end of expiration due to the huge pressure gradients accompanying the respiratory cycle in COPD patients; 4) measurements were performed in the early recovery period (approximately 2 min) after symptom-limited exercise. The timeline of pulmonary and intrathoracic pressures changes during the brief time interval from peak exercise to their measurement in early recovery is not well known, leading to possible underestimation.

In non-severe COPD patients with preserved LV systolic function, the combined ESE-CPX test can reliably identify stress-induced LVDD, the early diagnosis and proper management of which may facilitate the prevention of cardiovascular complications. Although none of the routine clinical and CPET parameters predicted increased E/e', the high prevalence of exercise-induced LVDD in these patients indicates the need for performing stress echocardiography.

Acknowledgment We thank Professor Vukov for performing the statistical analysis.

Funding None.

Ethical approval was obtained from the Ethics Committee of the Medical University, Sofia, protocol 5/12.03.2018.

Declaration of authorship all authors designed the study; contributed to the conception of the study, analysis, and interpretation of data; drafted the manuscript; revised the manuscript critically; gave their final approval of the version to be published; and agree to be countable for all aspects of the study.

Competing interest All the authors have completed the Unified Competing interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare no support from any organizations that might have an interest in the submitted work and no other relationships or activities that could appear to have influenced the submitted work.

References

1 Ford ES, Murphy LB, Khayjou O, Giles WH, Holt JB, Croft JB. Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020. Chest. 2015;147:31-45. Medline:25058738 doi:10.1378/chest.14-0972

2 Curkendall SM, Deluise C, Jones JK, Lanes S, Stang MR, Goehring E Jr, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease. Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16:63-70. Medline:16039877 doi:10.1016/j.annepidem.2005.04.008

3 Rutten FH, Cramer MJ, Grobbbee DE, Sachs AP, Kerkels JH, Lammers JW, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005;26:1887-94. Medline:15860516 doi:10.1093/eurheartj/ehi291

4 Sabit R, Bolton CE, Fraser AG, Edwards JM, Edwards PH, Ionescu AA, et al. Sub-clinical left and right ventricular dysfunction in patients with COPD. Respir Med. 2010;104:1171-8. Medline:20185285 doi:10.1016/j.rmed.2010.01.020

5 Altor P, van de Sand K, Nell C, Figiel JH, Greulich T, Vogelmeier CF, et al. Airflow limitation in COPD is associated with increased left ventricular wall stress in coincident heart failure. Respir Med. 2015;109:1131-7. Medline:26231928 doi:10.1016/j.rmed.2015.07.012

6 López-Sánchez M, Munoz-Esquerre M, Huertas D, Gonzalez-Costello J, Ribas J, Manresa F, et al. High prevalence of left ventricle diastolic dysfunction in severe COPD associated with a low exercise capacity: a cross-sectional study. PLoS One. 2013;8:e68034.
7 Neillan TG, Bakker JP, Sharma B, Owens RL, Farhad H, Shah RV, et al. T1 measurements for detection of expansion of the myocardial extracellular volume in chronic obstructive pulmonary disease. Can J Cardiol. 2014;30:1668-75. Medline:25442461 doi:10.1016/j.cjca.2014.08.006

8 Vitarelli A, Conde Y, Cimino E, Stellato S, D'Orazio S, D'Angeli I, et al. Assessment of right ventricular function by strain rate imaging in chronic obstructive pulmonary disease. Eur Respir J. 2006;27:268-75. Medline:16452579 doi:10.1183/09031936.06.00072005

9 Barr RG, Blueenke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010;362:217-27. Medline:20089972 doi:10.1056/NEJMoa0808836

10 Fisk M, McEniery CM, Gale n, Mäki-Petäjä K, Forman JR, Munnery M, et al. Surrogate markers of cardiovascular risk and chronic obstructive pulmonary disease: a large case-controlled study. Hypertension. 2018;71:499-506. Medline:29358458 doi:10.1161/ HYPERTENSIONAHA.117.10151

11 Smith BM, Kawut SM, Blueenke DA, Basner RC, Gomes AS, Hoffman E, et al. Impaired left ventricular filling in COPD and emphysema: is it the heart or the lungs? The Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study. Chest. 2013;144:1143-51. Medline:23764937 doi:10.1378/chest.13-0183

12 Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263-71. Medline:23684677 doi:10.1016/j.jacc.2013.02.092

13 Fu M, Zhou J, Thunström E, Almgren T, Grote L, Bollano E, et al. Optimizing the management of heart failure with preserved ejection fraction in the elderly by targeting comorbidities (OPTIMIZE-HFPEF). J Card Fail. 2016;22:539-44. Medline:26820355 doi:10.1016/j.cardfail.2016.01.011

14 O'Donnell DE, Elbeyahi AF, Faisal A, Webb KA, Neder JA, Mahler DA, et al. Exertional dyspnea in COPD: the clinical utility of cardiopulmonary exercise testing. Eur Respir Rev. 2016;25:333-47. Medline:27581832 doi:10.1183/09031936.0054-2016

15 Guazzi M, Myers J, Peberdy MA, Bensimhon D, Chase P, Arena R. Cardiopulmonary exercise testing variables reflects the degree of diastolic dysfunction in patients with heart failure-normal ejection fraction. J Cardiopulm Rehabil Prev. 2010;30:165-72. Medline:20216325 doi:10.1097/HCR.0b013e3181d0c1ad

16 Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319-38. Medline:16055882 doi:10.1183/09031936.05.0034805

17 ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111-7. Medline:12091180 doi:10.1164/ajccm.166.1.at1102

18 Guazzi M, Arena R, Halle M, Piepoli M, Myers J, Lavie C. 2016 focused update: clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Circulation. 2016;133:694-711. Medline:27143685 doi:10.1161/ CIRCULATIONAHA.116.008800

19 Mitchell C, Rahko P, Blauvelt L, Canaday B, Finsvank J, Foster M, et al. Guidelines For Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations From The American Society Of Echocardiography. J Am Soc Echocardiogr. 2019;32:1-64. Medline:30282592 doi:10.1016/j. echo.2018.06.004

20 Lancellotti P, Moura L, Pierard LA, Agricola E, Popescu BA, Tribouilloy C, et al. European Association of Echocardiography European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease). Eur J Echocardiogr. 2010;11:307-32. Medline:20435783 doi:10.1093/eurheartj/eqj031

21 Rudski LG, Lai WW, Afifajo I, Hua L, Handschumacher MD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography, J Am Soc Echocardiogr. 2010;23:685-713. Medline:20620859 doi:10.1016/j.echo.2010.05.010

22 Galil N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67-119. Medline:26320113 doi:10.1093/eurheartj/ehv317

23 Kovacs G, Berghold A, Scheidt S, Olszewski H, Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J. 2009;34:888-94. Medline:19324955 doi:10.1183/09031936.00145608

24 Mannino DM, Braman S. the epidemiology and economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2007;4:502-6. Medline:17878461 doi:10.1513/pats.200701-001FM

25 Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med. 2013;1:73-83. Medline:24321806 doi:10.1016/s2213-2600(12)70060-7

26 Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3:631-9. Medline:26208998 doi:10.1016/s2213-2600(15)00241-6

27 Fisk M, McEniery CM, Gale N, Mäki-Petäjä K, Forman JR, Munnery M, et al. doi:10.1378/chest.13-0183

Medline:27581832 doi:10.1183/09031936.0054-2016

DOIs: 10.1183/09031936.0054-2016; 10.1183/09031936.00145608; 10.1093/eurheartj/ehv317; 10.1093/pats.200701-001FM; 10.1016/s2213-2600(15)00241-6

www.cmj.hr
M, et al. Surrogate markers of cardiovascular risk and chronic obstructive pulmonary disease: a large case-controlled study. Hypertension. 2018;71:499-506. Medline:29358458 doi:10.1161/HYPERTENSIONAHA.117.10151

28 Neilan TG, Bakker JP, Sharma B, Owens RL, Farhad H, Shah RV, et al. T1 measurements for detection of expansion of the myocardial extracellular volume in chronic obstructive pulmonary disease. Can J Cardiol. 2014;30:1668-75. Medline:25442461 doi:10.1016/j.cjca.2014.08.006

29 Anderson WJ, Lipworth BJ, Rekhraj S, Struthers AD, George J. Left ventricular hypertrophy in COPD without hypoxemia: the elephant in the room. Chest. 2013;143:91-7. Medline:22797769 doi:10.1378/chest.12-0775

30 Schoos M, Dalsgaard M, Kjørgaard DJ, Moesby D, Jensen S, Steffensen I, et al. Echocardiographic predictors of exercise capacity and mortality in chronic obstructive pulmonary disease. BMC Cardiovasc Disord. 2013;13:32-45. Medline:24118827 doi:10.1186/1471-2261-13-84

31 Sabit R, Bolton CE, Fraser AG, Edwards JM, Edwards PH, Ionescu AA, et al. Sub-clinical left and right ventricular dysfunction in patients with COPD. Respir Med. 2010;104:1171-8. Medline:20185285 doi:10.1016/j.rmed.2010.01.020

32 Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation. 2003;107:714-20. Medline:12578874 doi:10.1161/01.CIR.0000048123.22359.A0

33 Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright P, Hoffman EA, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010;362:217-27. Medline:20089972 doi:10.1056/NEJMoa0808836

34 Watz H, Waschki B, Meyer T, Kretschmar G, Kirsten A, Claussen M, et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest. 2010;138:32-8. Medline:20190002 doi:10.1378/chest.09-2810

35 Funk GC, Lang I, Schenk P, Valipour A, Hartl S, Burghuber OC, et al. Left ventricular diastolic dysfunction in patients with COPD in the presence and absence of elevated pulmonary arterial pressure. Chest. 2008;133:1354-9. Medline:18339780 doi:10.1378/chest.07-2686

36 MacKay JD, McAllister DA, Johnston S, Raftis J, McGuinness C, Deans A, et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax. 2011;66:769-74. Medline:21507906 doi:10.1136/thx.2010.157529

37 Mills NL, Miller JJ, Anand A, Robinson SD, Frazer GA, Anderson D, et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax. 2008;63:306-11. Medline:18024535 doi:10.1136/thx.2007.083493

38 Peinado VI, Barbera JA, Ramirez J, Gomez FP, Roca J, Jover L, et al. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am J Physiol. 1998;274:908-13. Medline:9609729

39 Andreas S, Anker SD, Scanlon PD, Somers VK. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest. 2005;128:3618-25. Medline:16304321 doi:10.1378/chest.128.5.3618

40 Vanfleteren LE, Spruit MA, Groenen M, Gaffron S, van Empel VP, Bruijnzeel PL, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187:728-35. Medline:23392440 doi:10.1164/rccm.201209-1665OC

41 Burgel PR, Paillasaur JE, Peene B, Dusser D, Roche N, Coolen J, et al. Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortality. PLoS One. 2012;7:14-21. Medline:23236428 doi:10.1371/journal.pone.0051048

42 Garcia-Aymerich J, Gomez FP, Benet M, Farrero E, Basagana X, Gayete A, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax. 2011;66:430-7. Medline:21177668 doi:10.1136/thx.2010.154484

43 Nedeljkovic I, Banovic M, Stepanovic J, Giga V, Djordjevic-Dikic A, Trifunovic D, et al. The combined exercise stress echocardiography and cardiopulmonary exercise test for identification of masked heart failure with preserved ejection fraction in patients with hypertension. Eur J Prev Cardiol. 2016;23:71-7. Medline:26358991 doi:10.1177/2047487315604836

44 Kaiser T, Datta D. Can diastolic dysfunction be identified on cardiopulmonary exercise testing. Chest. 2017;152:976. doi:10.1016/j.chest.2017.08.1011

45 Guazzi M, Myers J, Arena R. Cardiopulmonary exercise testing in the clinical and prognostic assessment of diastolic heart failure. J Am Coll Cardiol. 2005;46:1883-90. Medline:16286176 doi:10.1016/j.jacc.2005.07.051